Pilot Study of the Prospective Identification of Changes in Cognitive Function During Chemotherapy Treatment for Advanced Ovarian Cancer
Change in cognitive function is increasingly being recognized as an adverse outcome related to chemotherapy treatment. These changes need not be severe to impact patient functional ability and quality of life. The primary goal of this study was to determine if there is evidence of changes in the cognitive function domains of attention, processing speed, and response time among women with newly diagnosed advanced ovarian cancer who receive chemotherapy. Eligible patients were women diagnosed with stage III–IV epithelial ovarian or primary peritoneal cancer who had not yet received chemotherapy but who were prescribed a minimum of six cycles (courses) of chemotherapy treatment. Cognitive function was assessed by a computerized, Web-based assessment (attention, processing speed, and reaction time) and by patient self-report. Cognitive function was assessed at three time points: prior to the first course (baseline), course three, and course six. Medical records were reviewed to abstract information on chemotherapy treatment, concomitant medications, and blood test results (eg, hemoglobin, CA-125). Of the 27 eligible participants, 92% and 86% demonstrated cognitive impairments from baseline to course three and from baseline to course six of chemotherapy, respectively. Impairment was detected in two or more cognitive domains among 48% (12 of 25) and 41% (9 of 22) of participants at course three and course six of chemotherapy, respectively. This study shows evidence of decline in cognitive function among women being treated for ovarian cancer. There is a need for additional, prospective research to better understand the impact of chemotherapy on cognitive function among ovarian cancer patients so that effective preventive and treatment strategies can be developed.
Acknowledgments
This study was funded by an investigator-initiated grant from Ortho Biotech, Inc., to the University of Arizona Cancer Center. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect those of Ortho Biotech.
References1
1 J.S. Wefel, A.E. Kayl and C.A. Meyers, Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target, Br J Cancer 90 (9) (2004), pp. 1691–1696. View Record in Scopus | Cited By in Scopus (48)
2 A.J. Saykin, T.A. Ahles and B.C. McDonald, Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives, Semin Clin Neuropsychiatry 8 (4) (2003), pp. 201–216. View Record in Scopus | Cited By in Scopus (63)
3 L.M. Hess and K.C. Insel, Chemotherapy-related change in cognitive function: a conceptual model, Oncol Nurs Forum 34 (5) (2007), pp. 981–994. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (11)
4 C.A. Meyers, Neurocognitive dysfunction in cancer patients, Oncology (Williston Park) 14 (1) (2000), pp. 75–79 discussion 9, 81–82, 85. View Record in Scopus | Cited By in Scopus (68)
5 M.L. Hensley, D.D. Correa and H. Thaler et al., Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning, Gynecol Oncol 102 (2) (2006), pp. 270–277. Article |
6 C.A. Meyers and J.S. Wefel, The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity, J Clin Oncol 21 (19) (2003), pp. 3557–3558. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (55)
7 J. Vardy, K. Wong and Q.L. Yi et al., Assessing cognitive function in cancer patients, Support Care Cancer 14 (11) (2006), pp. 1111–1118. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (27)
8 J. Vardy, S. Rourke and I.F. Tannock, Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research, J Clin Oncol 25 (17) (2007), pp. 2455–2463. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (58)
9 H.Q. Huang, M.F. Brady, D. Cella and G. Fleming, Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a Gynecologic Oncology Group study, Int J Gynecol Cancer 17 (2) (2007), pp. 387–393. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (16)
10 E.A. Calhoun, E.E. Welshman and C.H. Chang et al., Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy, Int J Gynecol Cancer 13 (6) (2003), pp. 741–748. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (56)
11 D.M. Erlanger, D.J. Feldman, D. Kaplan and A. Theodoracopulos, Development and validation of the cognitive stability index, a Web-based protocol for monitoring change in cognitive function, Arch Clin Neuropsychol 15 (2000), pp. 693–694. Abstract |
12 D.M. Erlanger, T. Kaushik, D. Broshek, J. Freeman, D. Feldman and J. Festa, Development and validation of a Web-based screening tool for monitoring cognitive status, J Head Trauma Rehabil 17 (5) (2002), pp. 458–476. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (22)
13 G.J. Chelune, R.K. Heaton and R.A.W. Lehman, Neuropsychological and personality correlates of patients' complaints of disability. In: G. Goldstein and R.E. Tarter, Editors, Advances in Clinical Neuropsychology, Plenum Press, New York (1986).
14 C.E. Schwartz, E. Kozora and Q. Zeng, Towards patient collaboration in cognitive assessment: specificity, sensitivity and incremental validity of self-report, Ann Behav Med 18 (3) (1996), pp. 177–184. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (16)
15 K. Paraska and C.M. Bender, Cognitive dysfunction following adjuvant chemotherapy for breast cancer: two case studies, Oncol Nurs Forum 30 (3) (2003), pp. 473–478. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (15)
16 E. Kozora, M.C. Ellison and S. West, Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery, Arthritis Rheum 55 (4) (2006), pp. 628–635. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (36)
17 T.A. Ahles, A.J. Saykin and C.T. Furstenberg et al., Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma, J Clin Oncol 20 (2) (2002), pp. 485–493. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (251)
18 P. Klepstad, P. Hilton, J. Moen, B. Fougner, P.C. Borchgrevink and S. Kaasa, Self-reports are not related to objective assessments of cognitive function and sedation in patients with cancer pain admitted to a palliative care unit, Palliat Med 16 (6) (2002), pp. 513–519. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (25)
19 S.B. Schagen, F.S. van Dam, M.J. Muller, W. Boogerd, J. Lindeboom and P.F. Bruning, Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma, Cancer 85 (3) (1999), pp. 640–650. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (263)
20 S.B. Schagen, M.J. Muller and W. Boogerd et al., Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients, Ann Oncol 13 (9) (2002), pp. 1387–1397. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (99)
21 F.S. van Dam, S.B. Schagen and M.J. Muller et al., Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy, J Natl Cancer Inst 90 (3) (1998), pp. 210–218. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (322)
22 D.L. Fairclough and D.F. Cella, Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions, Qual Life Res 5 (1996), pp. 321–329. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (75)
23 C.L. Burton, E. Strauss, D.F. Hultsch and M.A. Hunter, Cognitive functioning and everyday problem solving in older adults, Clin Neuropsychol 20 (3) (2006), pp. 432–452. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (20)
